Peptron CEO buys 10,000 shares, expresses confidence in joint research with Eli Lilly

Choi Ho-il, the CEO of Peptron, has acquired 10,000 company shares via open market purchases, signaling strong confidence in the firm's future prospects. This action comes amid recent market volatility and misunderstandings surrounding Peptron's joint research initiatives with the global pharmaceutical giant Eli Lilly.

The CEO's direct investment in company stock is interpreted as a strategic move to reassure investors and highlight the company's technological capabilities and growth potential. Peptron stated that Choi Ho-il's acquisition brings his total shareholding to 1,676,662 shares, increasing his stake in the company.

This initiative by the management aims to counter any negative market sentiment that may have arisen from the ongoing collaboration with Eli Lilly. By personally increasing his equity, CEO Choi Ho-il underscores his belief in the value and future success of Peptron's research and development efforts.

The company is emphasizing its commitment to transparency and its strong technological foundation as it navigates the complexities of its partnership with Eli Lilly and seeks to build investor confidence.

“

We are confident in our technology and growth potential.